See our story about this Mountain View, Calif., biotech at VentureBeat Life Sciences.
Chemokine-drug maker ChemoCentryx files for $58M IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.